Visualize how your peptide clears from the body — half-life, steady state, and accumulation for every injection schedule.
Half-Life
~30 min
Time for 50 % to be eliminated
Steady State
~2 h
≈ 4.3 half-lives
Accumulation
×1.00
Cmax at steady state ÷ Cmax first dose
Gone After
~4 h
after last dose
| Hour | % of peak |
|---|---|
| 0 | 100 |
| 8.575 | 0 |
| 17.15 | 0 |
| 25.01 | 24.7 |
| 33.585 | 0 |
| 42.16 | 0 |
| 50.021 | 6.1 |
| 58.596 | 0 |
| 67.171 | 0 |
| 75.031 | 1.5 |
| 83.606 | 0 |
| 92.181 | 0 |
| 100.042 | 0.4 |
| 108.617 | 0 |
| 117.192 | 0 |
| 125.052 | 0.1 |
| 133.627 | 0 |
| 142.202 | 0 |
| 150.063 | 0 |
| 158.638 | 0 |
| 167.213 | 0 |
Source: Literature estimate. Research tool. Uses a simplified first-order elimination model and normalizes concentration to % of peak. Not a medical or dosing recommendation. Tesamorelin: ~30 min.
Tesamorelin has a reported half-life of about 30 minutes. Under a daily dosing schedule, the peptide clears entirely within a few hours. Steady state is reached at roughly 4.3 half-lives, about 2 hours, and there is no meaningful accumulation between daily doses.
The blue line plots concentration as a percentage of the first-dose peak. The dashed reference line marks the steady-state peak. After the last dose, concentration drops below 1 % of the peak after about 3.5 hours, seven half-lives.
Tesamorelin is an FDA-approved GHRH analogue that stimulates endogenous growth hormone release. It is studied at daily doses of 1 to 2 mg via subcutaneous injection. The very short half-life means each dose produces a brief GH pulse followed by complete clearance, mimicking the natural pulsatile pattern of GH secretion.